These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

181 related articles for article (PubMed ID: 30853812)

  • 21. Subcutaneous versus intravenous administration of trastuzumab: preference of HER2+ breast cancer patients and financial impact of its use.
    Lazaro Cebas A; Cortijo Cascajares S; Pablos Bravo S; Del Puy Goyache Goñi M; Gonzalez Monterrubio G; Perez Cardenas MD; Ferrari Piquero JM
    J BUON; 2017; 22(2):334-339. PubMed ID: 28534353
    [TBL] [Abstract][Full Text] [Related]  

  • 22. Trastuzumab and thyroid dysfunction: An association to be aware of.
    Sánchez-Bayona R; Garcia Del Barrio MA; Alegre E; Fernandez-Hidalgo OA; Eslava MS
    J Cancer Res Ther; 2022; 18(4):1183-1185. PubMed ID: 36149184
    [TBL] [Abstract][Full Text] [Related]  

  • 23. Pharmacokinetics of Trastuzumab After Subcutaneous and Intravenous Administration in Obese Patients.
    González García J; Gutiérrez Nicolás F; Ramos Díaz R; Nazco Casariego GJ; Viña Romero MM; Llabres Martinez M; Llanos Muñoz M; Batista López JN; Jiménez Sosa A; Ceballos Lenza I; Cruz Jurado J
    Ann Pharmacother; 2020 Aug; 54(8):775-779. PubMed ID: 31971005
    [No Abstract]   [Full Text] [Related]  

  • 24. White Paper on the Value of Time Savings for Patients and Healthcare Providers of Breast Cancer Therapy: The Fixed-Dose Combination of Pertuzumab and Trastuzumab for Subcutaneous Injection as an Example.
    Jackisch C; Manevy F; Frank S; Roberts N; Shafrin J
    Adv Ther; 2022 Feb; 39(2):833-844. PubMed ID: 34988876
    [TBL] [Abstract][Full Text] [Related]  

  • 25. Phase III study to evaluate patient's preference of subcutaneous versus intravenous trastuzumab in HER2-positive metastatic breast cancer patients: Results from the ChangHER study (GEICAM/2012-07).
    Ciruelos EM; Montaño A; Rodríguez CA; González-Flores E; Lluch A; Garrigós L; Quiroga V; Antón A; Malón D; Chacón JI; Velasco M; Gonzalez-Cortijo L; Jolis L; Echarri MJ; Muñoz M; Pascual T; Amigo Y; Casas M; Carrasco E; Casas A
    Eur J Cancer Care (Engl); 2020 Jul; 29(4):e13253. PubMed ID: 32578279
    [TBL] [Abstract][Full Text] [Related]  

  • 26. Switching between intravenous and subcutaneous trastuzumab: Safety results from the PrefHer trial.
    Gligorov J; Curigliano G; Müller V; Knoop A; Jenkins V; Verma S; Osborne S; Lauer S; Machackova Z; Fallowfield L; Pivot X
    Breast; 2017 Aug; 34():89-95. PubMed ID: 28549309
    [TBL] [Abstract][Full Text] [Related]  

  • 27. Economic benefits of subcutaneous trastuzumab administration: A single institutional study from Karolinska University Hospital in Sweden.
    Hedayati E; Fracheboud L; Srikant V; Greber D; Wallberg S; Linder Stragliotto C
    PLoS One; 2019; 14(2):e0211783. PubMed ID: 30716137
    [TBL] [Abstract][Full Text] [Related]  

  • 28. Cost-minimization analysis of subcutaneous versus intravenous trastuzumab administration in Chilean patients with HER2-positive early breast cancer.
    Rojas L; Muñiz S; Medina L; Peña J; Acevedo F; Pinto MP; Sanchez C
    PLoS One; 2020; 15(2):e0227961. PubMed ID: 32023267
    [TBL] [Abstract][Full Text] [Related]  

  • 29. Intravenous and subcutaneous formulations of trastuzumab, and trastuzumab biosimilars: implications for clinical practice.
    Waller CF; Möbius J; Fuentes-Alburo A
    Br J Cancer; 2021 Apr; 124(8):1346-1352. PubMed ID: 33589773
    [TBL] [Abstract][Full Text] [Related]  

  • 30. Fixed-dose combination of pertuzumab and trastuzumab for subcutaneous injection in patients with HER2-positive breast cancer: A multidisciplinary approach.
    DuMond B; Patel V; Gross A; Fung A; Weber S
    J Oncol Pharm Pract; 2021 Jul; 27(5):1214-1221. PubMed ID: 33719721
    [TBL] [Abstract][Full Text] [Related]  

  • 31. Preference for the fixed-dose combination of pertuzumab and trastuzumab for subcutaneous injection in patients with HER2-positive early breast cancer (PHranceSCa): A randomised, open-label phase II study.
    O'Shaughnessy J; Sousa S; Cruz J; Fallowfield L; Auvinen P; Pulido C; Cvetanovic A; Wilks S; Ribeiro L; Burotto M; Klingbiel D; Messeri D; Alexandrou A; Trask P; Fredriksson J; Machackova Z; Stamatovic L;
    Eur J Cancer; 2021 Jul; 152():223-232. PubMed ID: 34147014
    [TBL] [Abstract][Full Text] [Related]  

  • 32. Cost minimization analysis of treatment with intravenous or subcutaneous trastuzumab in patients with HER2-positive breast cancer in Spain.
    Lopez-Vivanco G; Salvador J; Diez R; López D; De Salas-Cansado M; Navarro B; De la Haba-Rodríguez J
    Clin Transl Oncol; 2017 Dec; 19(12):1454-1461. PubMed ID: 28577152
    [TBL] [Abstract][Full Text] [Related]  

  • 33. Safety profile of subcutaneous trastuzumab in patients with HER2-positive early breast cancer: The French HERmione non-interventional prospective study.
    Jacquin JP; Uwer L; Savignoni A; Ferrero JM; Lortholary A; Solub D; Delaporte F; Chalabi N; Pibre S; Belkacemi Y
    Breast; 2020 Feb; 49():1-7. PubMed ID: 31670262
    [TBL] [Abstract][Full Text] [Related]  

  • 34. Six versus 12 months' adjuvant trastuzumab in patients with HER2-positive early breast cancer: the PERSEPHONE non-inferiority RCT.
    Earl H; Hiller L; Vallier AL; Loi S; McAdam K; Hughes-Davies L; Rea D; Howe D; Raynes K; Higgins HB; Wilcox M; Plummer C; Mahler-Araujo B; Provenzano E; Chhabra A; Gasson S; Balmer C; Abraham JE; Caldas C; Hall P; Shinkins B; McCabe C; Hulme C; Miles D; Wardley AM; Cameron DA; Dunn JA
    Health Technol Assess; 2020 Aug; 24(40):1-190. PubMed ID: 32880572
    [TBL] [Abstract][Full Text] [Related]  

  • 35. Comparison of subcutaneous and intravenous administration of trastuzumab: a phase I/Ib trial in healthy male volunteers and patients with HER2-positive breast cancer.
    Wynne C; Harvey V; Schwabe C; Waaka D; McIntyre C; Bittner B
    J Clin Pharmacol; 2013 Feb; 53(2):192-201. PubMed ID: 23436264
    [TBL] [Abstract][Full Text] [Related]  

  • 36. Cost-effectiveness of six months versus 1-year adjuvant trastuzumab in HER2 positive early breast cancer in Egypt.
    Elsisi GH; Nada Y; Rashad N; Carapinha J; Noor AO; Almasri DM; Zaidy MA; Foad A; Khaled H
    J Med Econ; 2020 Jun; 23(6):575-580. PubMed ID: 32011199
    [No Abstract]   [Full Text] [Related]  

  • 37. Update on the subcutaneous administration of rituximab in Canadian cancer centres.
    Stewart D; Aucoin JS; Crosbie T; Forman M; Lye E; Christofides A; Mitha A
    Curr Oncol; 2020 Apr; 27(2):113-116. PubMed ID: 32489254
    [TBL] [Abstract][Full Text] [Related]  

  • 38. [Appropriate use of trastuzumab in Lazio Region: therapeutic scenarios and estimation of possible savings for the Regional Health Service.].
    Belleudi V; Rosa AC; Musicco F; Marchetti P; Martini N; Andriani A; Calamia T; Addis A
    Recenti Prog Med; 2019 Dec; 110(12):604-614. PubMed ID: 31909763
    [TBL] [Abstract][Full Text] [Related]  

  • 39. Neo-adjuvant and/or Adjuvant Subcutaneous Trastuzumab (Herceptin
    Schmidt M; KÜmmel S; Ruf-Doerdelmann A; Distelrath A; Wacker J; Schmatloch S; Busch-Liles S; LÜdtke-Heckenkamp K
    Anticancer Res; 2021 Jan; 41(1):485-496. PubMed ID: 33419847
    [TBL] [Abstract][Full Text] [Related]  

  • 40. Clinical characteristics and disease outcomes in ER+ breast cancer: a comparison between HER2+ patients treated with trastuzumab and HER2- patients.
    Li S; Wu J; Huang O; He J; Zhu L; Chen W; Li Y; Chen X; Shen K
    BMC Cancer; 2021 Jul; 21(1):807. PubMed ID: 34256710
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 10.